There have been no reports of overdose with ARCALYST (rilonacept) . Maximum weekly doses of up to 320 mg have been administered subcutaneously for up to approximately 18 months in a small number of patients with CAPS and up to 6 months in patients with an unapproved indication in clinical trials without evidence of dose-limiting toxicities. In addition, ARCALYST (rilonacept) given intravenously at doses up to 2000mgmonthly in another patient population for up to six months were tolerated without dose-limiting toxicities. The maximum amount of ARCALYST (rilonacept) that can be safely administered has not been determined.
In case of overdose, it is recommended that the subject be monitored for any signs or symptoms of adverse reactions or effects, and appropriate symptomatic treatment instituted immediately.
None.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/6/2009
Additional Arcalyst Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.